TrialCancer chemotherapy and pharmacology2017

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).

Tadahiro Shoji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.